The Omicron-based vaccine candidate developed by China’s Sinopharm is expected to complete clinical trials in three to four months, senior executives of the company said recently, adding that it will shift most manufacturing capacity to the upgraded vaccine if it is developed successfully. China National Biotech Group, a subsidiary of Sinopharm, was granted permission to conduct human trials of its …